HWG Holdings LP Buys 6,647 Shares of Eli Lilly and Company $LLY

Key Points

• HWG Holdings LP purchased 6,647 Eli Lilly shares worth approximately $7.69 million, making LLY about 1.8% of its portfolio. Institutional investors collectively own 82.53% of the stock.
• Analysts remain broadly bullish, with 25 Buy ratings and an average price target of $1,312.36; JPMorgan recently raised its target to $1,500.
• Eli Lilly reported strong quarterly results, including $8.38 in EPS and $22.97 billion in revenue, representing 47.7% year-over-year growth. However, insiders sold 13,500 shares worth nearly $16 million during the quarter, while the stock trades at roughly 40 times earnings.

HWG Holdings LP bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,647 shares of the company's stock, valued at approximately $7,691,000. Eli Lilly and Company makes up about 1.8% of HWG Holdings LP's investment portfolio, making the stock its 17th largest holding.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Puff Wealth Management LLC raised its stake in shares of Eli Lilly and Company by 4.6% during the 3rd quarter. Puff Wealth Management LLC now owns 297 shares of the company's stock worth $343,000 after purchasing an additional 13 shares in the last quarter. Retirement Wealth Solutions LLC raised its position in Eli Lilly and Company by 23.9% during the third quarter. Retirement Wealth Solutions LLC now owns 135 shares of the company's stock worth $156,000 after acquiring an additional 26 shares in the last quarter. Cooper Financial Group raised its position in Eli Lilly and Company by 9.5% during the third quarter. Cooper Financial Group now owns 5,776 shares of the company's stock worth $6,683,000 after acquiring an additional 502 shares in the last quarter. Elm3 Financial Group LLC lifted its stake in Eli Lilly and Company by 3.8% in the third quarter. Elm3 Financial Group LLC now owns 4,204 shares of the company's stock valued at $4,864,000 after acquiring an additional 152 shares during the last quarter. Finally, Canandaigua National Trust Co of Florida bought a new position in shares of Eli Lilly and Company in the 3rd quarter valued at about $19,155,000. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on LLY shares. Berenberg Bank set a $1,400.00 price objective on shares of Eli Lilly and Company and gave the stock a "buy" rating in a research note on Tuesday, September 15th. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an "overweight" rating in a research report on Monday, September 28th. UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a research note on Friday, August 7th. Wells Fargo & Company boosted their target price on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Finally, Sanford C. Bernstein increased their price target on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an "outperform" rating in a research note on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $1,312.36.

Insiders Place Their Bets

In related news, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 in the last quarter. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,186.95 on Thursday. The stock has a 50 day simple moving average of $1,173.51 and a 200 day simple moving average of $1,094.59. The stock has a market cap of $1.12 trillion, a P/E ratio of 39.83, a PEG ratio of 1.42 and a beta of 0.46. Eli Lilly and Company has a 1-year low of $783.85 and a 1-year high of $1,292.65. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same period in the prior year, the firm posted $6.31 EPS. The company's revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts anticipate that Eli Lilly and Company will post 36.66 earnings per share for the current year.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Jim Cramer said he would favor Lilly over Novo Nordisk for a three- to five-year investment horizon, calling Lilly a high-quality company. The endorsement reinforces bullish sentiment around Lilly’s long-term growth prospects. Jim Cramer’s comparison of Novo Nordisk and Eli Lilly
• Positive Sentiment: Investors are increasingly looking beyond current blockbusters to retatrutide, Lilly’s next-generation triple-hormone obesity treatment. Reported trial weight loss has exceeded Zepbound’s results, and a potential FDA filing in early 2027 provides a major future catalyst. Lilly’s retatrutide drug data
• Positive Sentiment: Recent coverage highlights additional growth opportunities in oncology, immunology, neuroscience, and an oral GLP-1 candidate, Foundayo. Lilly also reported favorable Foundayo data versus oral semaglutide, potentially strengthening its competitive position in diabetes and obesity care. Foundayo clinical data
• Neutral Sentiment: Analysts remain divided: Lilly’s rapid revenue growth and pipeline support a premium valuation, but the stock trades near 40 times trailing earnings, leaving limited room for execution disappointments. Lilly’s growth and valuation analysis
• Negative Sentiment: New World Health Organization childhood-obesity guidelines could increase scrutiny of pediatric obesity treatments and create additional regulatory or market-access challenges for Lilly and Novo Nordisk. WHO childhood-obesity guidelines

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.